Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemzar Proves a Point

This article was originally published in RPM Report

Executive Summary

FDA approval of Eli Lilly's oncology drug Gemzar for ovarian cancer against the recommendation of the agency's advisory committee shows FDA is serious about progression-free survival as a primary clinical endpoint.
Advertisement

Related Content

Nothing Random About It: The State of Cancer Drug Development at FDA
Lost in Translation: Interpreting Advisory Committees
Nothing Random About It: The State of Cancer Drug Development at FDA
Lost in Translation: Interpreting Advisory Committees
Hurry Up and Wait: The Slowdown in Accelerated Approvals

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel